Top of this page
Skip navigation, go straight to the content
R&D pipeline
The UCB pipeline delivers:
- a promising portfolio targeting severe diseases and addressing unmet medical needs
- focus on neurological and immunological diseases
- more convenient and effective treatments for patients and specialists.
UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.
Neurology
Immunology
| Indications | Phase 1 | Phase 2 | Phase 3 | Filed | ||
|---|---|---|---|---|---|---|
| bimekizumab (IL17AF) | psoriasis |  | ||||
| psoriatic arthritis |  | |||||
| axial spondyloarthritis | | |||||
| hidradenitis suppurativa | | |||||
| rozanolixizumab (FcRn) | myasthenia gravis |  | ||||
| immune thrombocytopenia | | |||||
| chronic inflammatory demyelinating polyneuropathy (CIDP) |  | |||||
| zilucoplan (C5) | myasthenia gravis | | ||||
| immune-mediated necrotizing myopathy (IMNM) |  | |||||
| amyotrophic lateral sclerosis1 | | |||||
| COVID-associated acute respiratory distress syndrome (ARDS)2 | | |||||
| Staccato® alprazolam | active epileptic seizure |  | ||||
| dapirolizumab pegol (CD40L) | systemic lupus erythematosus3 |  | ||||
| UCB0107 (Tau) | progressive supranuclear palsy (PSP) |  | ||||
| 1 Project |  | |||||
| 1 Project |  | |||||
1 In partnership with HEALEY ALS Platform Trial |
Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.